Risk-based quality management (RBQM) is becoming central to clinical trial oversight, with ICH E6(R3) emphasising proportional, patient-focused approaches. Sponsors and CROs are moving away from rigid monitoring plans toward strategies that embed quality throughout trial design and execution.

Discover Pharma spoke to Dan Beaudry, RBQM market owner at CluePoints, who said: “The shift to risk-based quality management allows teams to identify risks earlier and respond proportionately. It reduces oversight burden while supporting inspection readiness and aligning with ICH E6(R3) and ICH E8(R1) quality expectations.”

Here are his key messages through thought leadership.

RBQM integrates Quality by Design (QbD) principles, encouraging teams to identify Critical-to-Quality (CtQ) factors, define quality tolerance limits (QTLs), and set key risk indicators (KRIs) with escalation pathways. The approach can be summarised in five key stages:

1. Design for quality: Identify CtQ factors, assess risks, and translate them into QTLs and KRIs. Clear thresholds, escalation pathways, and proportionate controls help teams focus on what matters most to patient safety and data reliability.
2. Detect and prioritise risks: Central analytics and statistical monitoring help detect emerging risks across operational and clinical data. Regularly prioritising risks ensures limited resources are focused where they have the greatest impact.
3. Translate signals into action: Data-driven insights guide protocol adjustments, site training, or other interventions to mitigate risks. Documenting rationale ensures inspection readiness.
4. Optimise monitoring: Visit frequency and monitoring intensity are aligned to risk, rather than applied uniformly. This reduces unnecessary site burden while maintaining oversight quality.
5. Prove and improve: Teams review outcomes continuously, refine processes, and demonstrate RBQM effectiveness in documented decision trails.

Roundtable discussions organised by the Tufts Center for the Study of Drug Development and CluePoints highlight the importance of engaging all stakeholders early, including patients, to inform trial design and ensure practical implementation. Participants emphasised that regulators are increasingly expecting teams to connect design decisions to monitoring actions, prioritising critical thinking over paperwork.

Closing knowledge, technology, and infrastructure gaps is essential. Sponsors must manage fragmented data flows, metadata, blinding/unblinding, and oversight across multiple vendors. Integrated digital platforms support centralized monitoring, timely data refresh, and alignment of risk-based strategies across sponsors, CROs, and technology partners.

AI-enabled tools provide additional opportunities. Beaudry added: “Used properly, AI can help prioritise review, reduce low-value work, and support targeted monitoring while keeping all decision-making traceable and accountable.” When applied responsibly, AI can surface patterns in deviations, site variability, and emerging risk signals, but outputs must remain transparent, validated, and subject to human accountability.

Practical steps for implementation include:

• Engage regulators early to ensure proportionality, data integrity, and digital adoption meet expectations.
• Engage sites and patients to test feasibility, identify risks, and incorporate feedback into trial design.
• Apply QbD principles to proactively identify risks and ensure participant safety and critical data integrity remain central.
• Conduct cross-functional risk assessments to determine CtQ factors and define QTLs and KRIs.
• Establish centralized monitoring routines to detect and triage signals, and document rationale and outcomes.
• Foster a culture that rewards proactive risk management and open communication across functions.

RBQM represents a philosophical shift: quality is embedded from the start rather than added as a compliance exercise. Sponsors adopting systematic, risk-based approaches are better positioned to improve efficiency, strengthen inspection narratives, reduce patient and site burden, and respond quickly to risks.

With SCOPE 2026 highlighting both RBQM and AI, the conference offers an opportunity for industry stakeholders to share learnings and align practices. Successful adoption depends on sustained engagement, disciplined change management, and clear traceability from design decisions to daily actions.